-
Jan 17, 2025 | 
acrjournals.onlinelibrary.wiley.com | Leonard Calabrese |Michael Putman |Jeffrey A Sparks |Zachary S. Wallace
Corresponding Author Leonard H Calabrese DO Cleveland Clinic, Cleveland Clinic Lerner College of Medicine Corresponding author: Leonard H. Calabrese, D.O., Professor of Medicine, Cleveland Clinic Lerner College of Medicine, RJ Fasenmyer Chair of Clinical Immunology, Vice Chairman, Department of Rheumatic and Immunologic Diseases, 9500 Euclid Avenue, Desk A50, Cleveland, Ohio 44195, Phone: (216) 444-5258, Fax: (216) 445-7569.
-
Nov 21, 2024 | 
rheumnow.com | Michael Putman
Randomized controlled trials (RCTs) drive guidelines; guidelines drive clinical practice. Because updated guidelines lag trials by many years and dissemination of guidelines takes additional time, rheumatologists often practice “behind the data.” The 2024 ACR Guidelines for the Management of SLE Nephritis reaffirmed many of our typical practice patterns, including hydroxychloroquine for all, renin/angiotensin blockade, and favoring mycophenolate mofetil over cyclophosphamide.
-
Nov 18, 2024 | 
rheumnow.com | Michael Putman
Let me start by confessing something embarrassing: the immune system is just too complex for me to understand. I suspect the onslaught of new drugs with new mechanisms at ACR 2024 may have left many of you feeling similarly. This may be particularly true for the TYK/JAK/STAT signaling pathway, where each agent has a slightly-different combination of binding affinity to various JAK and TYK signaling dimers.
-
Nov 17, 2024 | 
rheumnow.com | Michael Putman
When the ACR Convergence 2024 abstract site went live, the first query I typed into the search bar was, “CAR-T.” I consider myself a CAR-T skeptic and would be surprised if the magical results from this NEJM case series replicate at scale, but it seems likely that CAR-T will revolutionize the care for (some) patients with rheumatic diseases. What is CAR-T? How can you get a healthy dose of it at ACR? And what does it mean for the future?
-
Jan 10, 2024 | 
lupus.bmj.com | Gabriel Figueroa-Parra |Michael Putman |Cynthia S. Crowson |Alí Duarte-García
DiscussionIn this study of pivotal phase III, randomised, placebo-controlled trials of new treatments for SLE and LN, many trials had an important degree of fragility, even among RCTs of medications that obtained approval.
-
Dec 15, 2023 | 
rheumnow.com | Michael Putman
The American College of Rheumatology (ACR) guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence. The guidelines expanded screening recommendations, which will likely result in overdiagnosis and overtreatment.
-
Dec 14, 2023 | 
rheumnow.com | Michael Putman
Of the many exciting advancements for patients with psoriatic arthritis at ACR Convergence, one upcoming therapy stood out: the dual IL-17A/F inhibitor bimekizumab. Nearly two dozen bimekizumab abstracts will be featured at this year’s meeting and it recently received authorization in Europe and the United States for psoriasis. That makes this the year I plan to figure out where this drug will be useful for my patients with psoriatic arthritis (PsA).
-
Dec 12, 2023 | 
rheumnow.com | Michael Putman
We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but prior to ACR Convergence 2023 there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described with respect to treatment strategies (116 patients).
-
Nov 15, 2023 | 
rheumnow.com | Michael Putman
We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but prior to ACR Convergence 2023 there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described with respect to treatment strategies (116 patients).
-
Nov 14, 2023 | 
rheumnow.com | Michael Putman
The American College of Rheumatology (ACR) guidelines for the diagnosis and management of interstitial lung disease, which includes rheumatoid arthritis interstitial lung disease (RA-ILD), has been one of the most controversial topics in the runup to ACR Convergence. The guidelines expanded screening recommendations, which will likely result in overdiagnosis and overtreatment.
